The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes
| Autor: | Signe Stensen, Tina Vilsbøll, Bolette Hartmann, Jens F. Rehfeld, Filip K. Knop, Niels B. Dalsgaard, Laura S. Hansen, Nina L. Hansen, Lærke S. Gasbjerg, Jens J. Holst |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Denmark 030209 endocrinology & metabolism Type 2 diabetes Carbohydrate metabolism Placebo Placebos 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Double-Blind Method Glucagon-Like Peptide 1 Diabetes mellitus Internal medicine Insulin-Secreting Cells medicine Humans Acarbose Aged Aged 80 and over Cross-Over Studies business.industry General Medicine Middle Aged medicine.disease Postprandial Period Crossover study Metformin Postprandial Diabetes Mellitus Type 2 Gastric Emptying 030220 oncology & carcinogenesis Female Insulin Resistance business medicine.drug |
| Zdroj: | European journal of endocrinology. 184(3) |
| ISSN: | 1479-683X |
| Popis: | Aims The alpha-glucosidase inhibitor acarbose is believed to reduce plasma glucose by delaying hydrolysis of carbohydrates. Acarbose-induced transfer of carbohydrates to the distal parts of the intestine increases circulating glucagon-like peptide 1 (GLP-1). Using the GLP-1 receptor antagonist exendin(9–39)NH2, we investigated the effect of acarbose-induced GLP-1 secretion on postprandial glucose metabolism in patients with type 2 diabetes. Methods In a double-blinded, placebo-controlled, randomized, crossover study, 15 participants with metformin-treated type 2 diabetes (age: 57–85 years, HbA1c: 40–74 mmol/mol) were subjected to two 14-day treatment periods with acarbose or placebo, respectively, separated by a 6-week wash-out period. At the end of each period, two randomized 4-h liquid mixed meal tests with concomitant infusion of exendin(9–39)NH2 and saline, respectively, were performed. Results Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. We observed no absolute difference in the exendin(9–39)NH2-induced increase in postprandial glucose excursions between placebo and acarbose periods, but relatively, postprandial glucose was increased by 119 ± 116% (mean ± s.d.) during exendin(9–39)NH2 infusion in the acarbose period vs a 39 ± 27% increase during the placebo period (P = 0.0163). Conclusions We confirm that acarbose treatment stimulates postprandial GLP-1 secretion in patients with type 2 diabetes. Using exendin(9–39)NH2, we did not see an impact of acarbose-induced GLP-1 secretion on absolute measures of postprandial glucose tolerance, but relatively, the effect of exendin(9–39)NH2 was most pronounced during acarbose treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|